Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
AES has a large clean-power and utility platform, but the March 2026 $15.00 cash merger agreement changes the public-equity question into a regulatory-close trade backed by a company-disclosed growth-capital problem.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
SEC filings, financial facts, source resources, and Goglides workspace context for Aardvark Therapeutics, Inc..
OpenAEP has turned the utility growth story into a transmission-led data-center and industrial load story, lifting its 2026-2030 capital plan to $78 billion while preserving 2026 guidance. The investment case now depends on rate recovery, balance-sheet funding and
OpenAmeren is pitching a regulated-utility growth story built on $31.8 billion of 2026-2030 infrastructure investment, but the thesis has to clear rate cases, customer bills, equity funding, and large-load demand.
OpenOfficial-source baseline for Aardvark Therapeutics using SEC submissions, SEC XBRL companyfacts, FY2025 10-K, Q1 FY2026 10-Q, company-filed results releases, clinical-update 8-Ks, prospectus filings, and peer filings.
OpenTag facets appear after tag usage counts are rebuilt.